Skip to content

Coherus Oncology, Inc.

CHRS

CIK 0001512762

← back to feed
Revenue (TTM)
$123.86M
+10.9% YoY Q1 Apr 2026
Net Income (TTM)
$167.34M
+489.4% YoY Q1 Apr 2026
EPS Diluted (TTM)
$1.49
+472.0% YoY Q1 Apr 2026
Gross Margin
93.7%
Q1 Apr 2026
Operating Margin
-138.4%
Q1 Apr 2026
Net Margin
135.1%
Q1 Apr 2026
Free Cash Flow (TTM)
−$201.91M
Q1 Apr 2026
Cash
$115.24M
Q1 Apr 2026
Total Debt
$73.66M
Q1 Apr 2026
Shares Outstanding
154.25M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings